NIKKEI 225
38,812.59 -107.67 (-0.28%) HANG SENG
19,433.14 +56.61 (+0.29%) CRUDE OIL
79.33 +0.10 (+0.13%) GOLD FUTURES
2,381.10 -4.40 (-0.18%) DOW
39,869.38 -38.62 (-0.10%) Bitcoin GBP
51,810.82 -256.25 (-0.49%)
Sanofi (SNW.DE)
| Previous close | 90.54 |
| Open | 90.50 |
| Bid | 89.92 x 200000 |
| Ask | 89.97 x 200000 |
| Day's range | 89.89 - 90.55 |
| 52-week range | 80.80 - 104.30 |
| Volume | |
| Avg. volume | 3,491 |
| Market cap | 112.352B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 24.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.15%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeut
- GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate d
- GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
